Singapore markets open in 3 hours 18 minutes
Straits Times Index
3,202.81 -39.19 (-1.21%) S&P 500
4,330.00 -72.20 (-1.64%) Dow
34,070.42 -370.46 (-1.08%) Nasdaq
13,223.99 -245.14 (-1.82%) Bitcoin USD
26,568.71 -593.39 (-2.18%) CMC Crypto 200
566.31 -9.95 (-1.73%)
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 60.37 |
| Open | 60.24 |
| Bid | 58.65 x 800 |
| Ask | 61.07 x 2200 |
| Day's range | 58.76 - 60.38 |
| 52-week range | 58.54 - 86.29 |
| Volume | |
| Avg. volume | 1,620,463 |
| Market cap | 13.179B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | 36.30 |
| EPS (TTM) | 1.62 |
| Earnings date | 30 Oct 2023 - 03 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 83.06 |
- Investing.com
FDA approves GSK's unique myelofibrosis treatment Ojjaara
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
ZacksWhy Is Incyte (INCY) Down 0.7% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business WireIncyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., August 22, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
© 2023 Yahoo. All rights reserved.
